Mariana Socal

MD/PhD, Associate Professor @JHSPH_HPM @JohnsHopkinsSPH. Working to make prescription drugs more affordable, accessible, and available to people who need them.

[Mariana Socal @dr_msocal]

Today the discussion is about fees that PBMs pay for consultants and brokers that help health insurance plans select a PBM. Should those fees be prohibited ?
I’ll be testifying on this topic at a Congressional hearing in a few minutes . Live stream here
https://t.co/REAVK2DP4p

[Mariana Socal @dr_msocal]

Honored to be delivering the David Rogers Health Policy Colloquium at @WeillCornell in #nyc today, discussing prescription drug #supplychain , #MadeInAmerica drugs and the @JohnsHopkins data #dashboard !
W/@EmmaBethMcGinty

More at https://t.co/BM8HxI5dhp

[Mariana Socal @dr_msocal]

Check out the latest #publichealth On Call podcast where we discuss TrumpRx and high drug prices

https://t.co/T8ejFjChpf

[Mariana Socal @dr_msocal]

The proceedings of our @JohnsHopkins & @theNASEM #Workshop on Make-Buy-Invest strategic actions to improve the US #pharmaceutical #supplychain are now publicly available !

https://t.co/5kBTuodv4s

[Mariana Socal @dr_msocal]

Busy meeting today at the #WhiteHouse to discuss incentives for #MadeInAmerica drugs.
How to can we identify which 💊 drugs are #MadeInAmerica 🇺🇸? The @JohnsHopkins prescription drug supply chain data dashboard 📝📈can help — https://t.co/BM8HxI5dhp

[Johns Hopkins University Bloomberg Center @JHUBloombergCtr]

Pharmaceutical supply chain issues in the U.S. have become a health and national security threat. In the latest #SpeedBrief, @JohnsHopkinsSPH's Mariana Socal discusses Hopkins' answer to this growing problem.

#supplychain #drugshortages

[Mariana Socal @dr_msocal]

I spend too much time unsubscribing from mailing lists for which I’ve never signed up in the first place.. 🥵 😾

[Mariana Socal @dr_msocal]

So grateful to receive this award , which will help elevate the @JohnsHopkins #pharmaceutical #supplychain data dashboard. Thank you, @JHadvocacy !More at https://t.co/BM8HxI5L6X

[Lerner Center for Public Health Advocacy @JHadvocacy]

Congratulations to the winners of the 2025 Sommer Klag Advocacy Impact Awards: Harry Barbee, PhD, and Mariana Socal, MD, PhD🎉.

Their pitch presentations showcased strong potential to create meaningful shifts in policy and practice within their fields👏🏽.

[Mariana Socal @dr_msocal]

So happy to see my former students and make new friends today at @UMBaltimore . It was great to learn about the cool things that this group is doing and discuss #drugpricing policies
#PhD #healthservicesresearch #pharmaceuticalpolicy

[Mariana Socal @dr_msocal]

We are all set for tomorrow’s @theNASEM Workshop on #pharmaceutical #supplychain at the Hopkins Bloomberg center in Washington DC!🎓 The view is amazing and the program will be even better !

More info here: https://t.co/epA85402Hp

[Mariana Socal @dr_msocal]

Excited to share our new piece at @Health_Affairs Forefront on recent Executive Orders on #drugpricing

https://t.co/WZHkWLTMsn

[Health Affairs @Health_Affairs]

In their new #Crossroads article, @jeromie_b, @MichelleM_Mello, @MarissaReitsma, @SoyeonKang_PhD, @Angela_HSR, @jlevy2, @dr_msocal, Antonio Trujillo, and Gerard Anderson of @JohnsHopkinsSPH, @Stanford, and @Georgetown discuss how, for many ideas in President Trump’s two executive orders on prescription drug pricing, a large evidence base can assist federal officials in translating promising broad ideas into specific policies that are likely to deliver cost savings to US patients and programs. https://t.co/aMl3kPpOJe

[Mariana Socal @dr_msocal]

If the peer-reviewer gods are watching , I hope they noticed that I finished all the reviews I had on my plate today. 😇 Now could they please make the people reviewing my papers finish their reviews too?!? Would be a true gift , thank you

[Mariana Socal @dr_msocal]

Today the spotlight is on the 1st year of the Inflation Reduction Act and its #drugpricing provisions. Thank you @gwlaw for inviting me to lead a very illustrious panel. Great discussion!
With @RESachs @ConorSheehey and Gregory Daniel from @EliLillyandCo

[Mariana Socal @dr_msocal]

Ozempic (semaglutide) is one of the drugs with the biggest affordability challenges today. It is used to treat type 2 diabetes and to protect these patients from cardiovascular problems. Given the high prevalence of diabetes in the US, every 💰dollar counts (5/5)

[Mariana Socal @dr_msocal]

Canada seems about to get generics for Ozempic (semaglutide), possibly as soon as January 2026. This is in stark contrast to the US, where generics will have to wait until at least 2032. What is the difference ? (1/5)

https://t.co/wSwW8qOl9I

[Mariana Socal @dr_msocal]

Should we have the same system as Canada ? Not necessarily, but this is an important lesson that our drug patent system must be revisited. - there are a few bills introduced in Congress to change this system , and they should receive more of our attention. (4/5)

[Mariana Socal @dr_msocal]

How to improve the affordability of pharmaceutical treatments for #diabetes? This call for action is now available for free download at @DiabetesCareADA

https://t.co/ivdH3QOS9f

[Mariana Socal @dr_msocal]

Had a wonderful discussion on “How to fix a broken system?” with the amazing @StevenKahn11 @LizSelvin @MarshallChinMD @SethABerkowitz
and @RepKimSchrier at the American Diabetes Association’s 85th #ADASciSessions in #Chicago.
Accompanying paper released in @DiabetesCareADA